Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Aug 30, 2024

SELL
$15.87 - $22.4 $63,480 - $89,600
-4,000 Closed
0 $0
Q2 2018

Aug 30, 2024

BUY
$18.56 - $22.45 $66,816 - $80,820
3,600 Added 900.0%
4,000 $86.1 Million
Q1 2018

Aug 30, 2024

SELL
$22.15 - $31.89 $111,259 - $160,183
-5,023 Reduced 92.62%
400 $8.86 Million
Q4 2017

Aug 30, 2024

SELL
$24.23 - $30.93 $51,900 - $66,252
-2,142 Reduced 28.31%
5,423 $165 Million
Q3 2017

Aug 30, 2024

SELL
$23.35 - $29.24 $16,858 - $21,111
-722 Reduced 8.71%
7,565 $183 Million
Q2 2017

Aug 30, 2024

BUY
N/A
8,287
8,287 $204 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $10.6B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.